AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02230319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Study NCT02230319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT04121663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total arthroscopic rotator cuff repair
Description: The equivalence of the two devices was compared by using control and experimental instruments during the operation
Study NCT04121663 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total arthroscopic rotator cuff repair
Description: The equivalence of the two devices was compared by using control and experimental instruments during the operation
Study NCT01137604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 24 mg lenvatinib capsules orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
Study NCT00886600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
Study NCT01137604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg administered intravenously every 2 weeks in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
Study NCT01409811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Given IV
Study NCT01409811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01409811 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo definitive lumpectomy or mastectomy
Study NCT00634101 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nelfilcon A
Description: contact lens
Study NCT00634101 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narafilcon A
Description: contact lens
Study NCT02273804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate for 9 months treatment, and then 27 months of follow-up Dose regimen will be determined according to theoretical weight (taken orally), escalated every 15 days. Patients who do not tolerate dose escalation will be reduced to the highest tolerated dose.
Study NCT02273804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken orally following to the same dose regimen according to theoretical weight
Study NCT02476266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Resistance training has been shown to improve balance and muscle weakness in those with PD as well as reducing the number of falls experienced, albeit not significantly. However to date no study has investigated forms of resistance training in the same study. To disentangle which form of resistance training might be more effective at reducing the risk of falls, improving balance and muscle strength, the proposed study will compare power training and conventional strength training.
Study NCT02476266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training
Description: Resistance training has been shown to improve balance and muscle weakness in those with PD as well as reducing the number of falls experienced, albeit not significantly. However to date no study has investigated forms of resistance training in the same study. To disentangle which form of resistance training might be more effective at reducing the risk of falls, improving balance and muscle strength, the proposed study will compare power training and conventional strength training.
Study NCT02010450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearable Blanket (Sleep Sack)
Study NCT02010450 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incentive Item
Study NCT02305810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily
Description: everolimus is a recently approved mTOR inhibitor in advanced progressing well/moderately differentiated pancreatic neuroendocrine tumors
Study NCT01988584 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord blood (hUCB) cells
Description: Autologous umbilical cord blood banked with the Cord Blood Registry.
Study NCT01988584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Infusion (Placebo)
Description: A total of 10 children (5 from each cohort) will be randomized to a placebo infusion at the baseline visit and then have the opportunity to cross-over to stem cell treatment at the 1yr. visit.
Study NCT01988584 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone marrow derived mononuclear cells (BMMNCs)
Description: Autologous stem cells from bone marrow harvest.
Study NCT00759564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-70,429 and PF-03709270
Description: Study Periods 1 and 2 will be separated by a minimum of 14 days. In Period 1, subjects will receive a single dose of CP-70429 (800 mg given as a 1.5 hour intravenous infusion), while in Period 2, subjects will receive a single oral dose of PF-03709270 (1000 mg).
Study NCT02829801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AAT and cognitive stimulation and rehabilitation of social tie.
Description: There are 8 workshops, one workshop per week. The workshops will begin with a 15 minute introductory activity allowing the establishment of the relationship with the dog and between the participants. Activities with the dog will be offered: games, caresses, brushing.~Then, a 40 minute cognitive stimulation will be offered. Finally, 5 minutes will be devoted to the closing of the session and to say goodbye to participants and the dog (pet him, play with him ...).
Study NCT02829801 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive stimulation and rehabilitation of social tie.
Description: There are 8 workshops, one workshop per week. The workshops will begin with an introductory activity of 15 minutes that will establish the relationship between the participants. Different topics will be proposed to foster communication and exchange.~Then, the same cognitive stimulation in the AAT arm will be offered.
Study NCT00886600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: placebo capsules to losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
Study NCT00886600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hydrochlorothiazide (HCTZ)
Description: open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with Sitting Diastolic Blood Pressure (SiDBP) ≥85 mm Hg after 4 weeks of losartan monotherapy (Combination Therapy Period)) orally once daily (q.d.) for 2 weeks
Study NCT00886600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (HCTZ)
Description: open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with Sitting Diastolic Blood Pressure (SiDBP) ≥85 mm Hg after 4 weeks of losartan monotherapy (Combination Therapy Period)) orally once daily (q.d.) for 2 weeks
Study NCT02763202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHS Transition Services
Description: The CHS Transition Services (CHS-TS) pathway includes the following seven components:~(i) Introduction to CHS-TS process prior to discharge (ii) Hospital follow-up evaluation within 72 hours either in home with paramedicine or in the CHS-TS clinic (iii) Medication reconciliation by a pharmacist within 72 hours (iv) Weekly contact with care management team (v) Entry into the Heart Success Program if appropriate (vi) Access to 24/7 phone support, 24/7 paramedicine visits, and same day clinic scheduling (vii) Coordinated transition to the next appropriate care location after 30 days from time of discharge
Study NCT01535456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FLT-PET scans
Description: FLT-PET scans prior to treatment, after Cycle 1, after Cycle 4
Study NCT00977821 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IVF
Study NCT00977821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oocyte Vitrification
Study NCT02381639 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: One interview of 90 minutes with a part of cognitive assessment and a part of self-assessment
Description: The content of the assessment will be the same for all subjects and will consist of a part of cognitive assessment (National Reading Test, Rey Osterreich Complex Figure, Hayling Sentence Completion Task, verbal memory, digit sequencing, token motor task, verbal fluencies, symbol coding, tower of London) and self-assessment (Mini International Neuropsychiatric Interview, Beck Depression Inventory, State Trait Anxiety Inventory, Wender Utah Rating Scale, Adult Self-Report Scale Symptom Checklist, UPPS Impulsive Behavior Scale)
Study NCT01119300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing algorithm
Description: Loading and monitoring dose according to genotype-guided dosing algorithm
Study NCT01119300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care
Study NCT03639909 — intervention group
Intervention type: PROCEDURE
Intervention: sweating function
Description: Sweating dysfunction by Sudoscan
Study NCT03639909 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiovascular function
Description: Cardiovascular (CV) tests
Study NCT01516086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate (FP)
Description: FP Inhalation BID
Study NCT00517829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Taxotere 60 mg/m2 as an intravenous (IV) infusion over 1 hour
Study NCT01516086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone Propionate (FP)
Description: FP Inhalation BID
Study NCT00357669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam 25 mg
Description: * Active Substance: Brivaracetam~* Pharmaceutical Form: Tablet~* Concentration: 25 mg~* Route of Administration: Oral use
Study NCT00357669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam 50 mg
Description: * Active Substance: Brivaracetam~* Pharmaceutical Form: Tablet~* Concentration: 50 mg~* Route of Administration: Oral use
Study NCT00517829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: ERBITUX 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.
Study NCT00517829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Eloxatin 130 mg/m2 IV over 2 hours
Study NCT01426139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention Biotronik Orsiro DES
Description: Stenting
Study NCT00576043 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simulator Training
Description: 3 weeks/2 hours per day of structured training for a total of 20 hours on the virtual endoscopy simulator with the GI-Mentor Virtual simulator device
Study NCT01097278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given orally
Study NCT01097278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: Given orally
Study NCT01097278 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT02443883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study NCT02343172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201
Study NCT02343172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Study NCT02008682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Administered subcutaneously (s.c., under the skin) once daily as add-on to the subject's stable pre-trial metformin dose.
Study NCT00357669 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Active Substance: Placebo Pharmaceutical Form: Tablet~* Concentration: 25 mg and 50 mg~* Route of Administration: Oral use
Study NCT00531791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone group
Description: Patients in the prednisone group will receive prednisone 40 mg per day with concomitant placebo diskus 2 inhalations twice a day for 10 days. All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.
Study NCT02008682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: Administered orally once daily as add-on to the subject's stable pre-trial metformin dose.
Study NCT01179009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Controlled IV ketamine infusion (0.00225mg/kg-min. \[18% (0.0125 mg/kg-min.).
Study NCT00531791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advair group
Description: Patients in the second group will receive Advair® 50/500 ug 2 inhalations twice daily with placebo pills once a day for 10 days (twice the regular dosage). All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.
Study NCT00312195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.
Study NCT01179009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Controlled IV ketamine infusion (0.00225mg/kg-min. \[18% (0.0125 mg/kg-min.).
Study NCT01179009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Participants will receive an approximately 5-day pretreatment of clonidine (max. dose 1mg/day divided doses) prior to and throughout the ketamine infusion.
Study NCT01179009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Participants will receive an approximately 5-day pretreatment of clonidine (max. dose 1mg/day divided doses) prior to and throughout the ketamine infusion.
Study NCT01179009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: IV saline (i.e. placebo ketamine)
Study NCT00345176 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein/zeaxanthin
Description: 10 mg lutein and 2 mg zeaxanthin (1 tablet) Placebo-DHA/EPA (2 soft-gel capsules)
Study NCT00345176 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA/EPA
Description: Placebo-lutein/zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
Study NCT00345176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lutein/zeaxanthin and DHA/EPA
Description: 10 mg lutein and 2 mg zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
Study NCT02202876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Tolerance Test
Description: 1.75 gm/kg to a maximum of 75 gm of an oral glucose solution
Study NCT00312195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match BTDS
Description: Placebo to match buprenorphine transdermal patch applied for 7-day wear.
Study NCT04721301 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab plus Maraviroc
Description: In the single treatment arm, all patients receive Nivolumab, Ipilimumab and Maraviroc
Study NCT01322282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine
Description: A single 10 mg dose of an experimental Cetirizine Orodispersible Tablet (ODT), with a 7-day washout period between visits
Study NCT02202876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Glycemic Index Meal
Description: isocaloric breakfasts - set the high glycemic index to 80~The nutrient composition of each meal will be 10 kcal per kg, 50% kcal from carbohydrates, 20% kcal from protein, and 30% kcal from fat
Study NCT01322282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine
Description: A single 10 mg dose of a marketed Cetirizine Film-Coated Tablet (FCT), with a 7-day washout period between visits
Study NCT02202876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Glycemic Index Meal
Description: isocaloric breakfasts - set the low glycemic index to 30~The nutrient composition of each meal will be 10 kcal per kg, 50% kcal from carbohydrates, 20% kcal from protein, and 30% kcal from fat
Study NCT02202876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test Soda
Description: Test soda containing 60% fructose and 40% glucose at a dose of 1.75 grams per kilogram body weight to a maximum of 75 grams.
Study NCT02202876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fruit juice
Description: Fruit juice containing a combination fructose, glucose, and sucrose at a dose of 1.75 grams per kilogram body weight to a maximum of 75 grams
Study NCT01600443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric
Description: Three catheterizations at least two hours apart using LoFric Primo 40 cm CH14.
Study NCT01600443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath
Description: Three catheterizations at least two hours apart using SpeediCath 40 cm CH14.
Study NCT01600443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath Compact Male
Description: Three catheterizations at least two hours apart using SpeediCath Compact Male 30 cm.
Study NCT04631146 — intervention group
Intervention type: DRUG
Intervention: Camrelizumab
Description: PD-1 inhibitors
Study NCT03472157 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle therapy
Description: Lifestyle habits (caloric intake and exercise) + pedometer
Study NCT03472157 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Two different types of bariatric surgery can be proposed: laparoscopic Roux-en-Y Gastric Bypass or a Laparoscopic sleeve gastrectomy
Study NCT03080246 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength Training Exercise
Study NCT01997411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon
Study NCT01997411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular Glucagon
Study NCT02563847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 0.52 g L-Tryptophan
Study NCT02563847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1.56 g L-Tryptophan
Study NCT02563847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1.56 g L-Leucine
Study NCT02563847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 50 g Xylitol
Study NCT02563847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 75 g Erythritol
Study NCT02563847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 75 g Glucose
Study NCT03655249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autogenic drainage
Description: Autogenic drainage is an airway clearance technique that attempts to obtain the optimal airflow to evacuate the secretions. This technique uses modulation of inspiratory and expiratory airflow at different breathing level within the vital capacity.
Study NCT03655249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aerosoltherapy
Description: Aerosolized drugs are individualized for each participants, in line with current standardized practice in our hospital. Those drugs will not be modified for the purpose of this study.
Study NCT03655249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosoltherapy
Description: Aerosolized drugs are individualized for each participants, in line with current standardized practice in our hospital. Those drugs will not be modified for the purpose of this study.
Study NCT02563847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 300 mL tap water
Study NCT04293822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine
Description: The patients will be randomly divided into 2 groups; each group contains 30 patients. Patients in both groups will be given the treatment in identical non-labeled bottles with a code and neither the patient nor the doctor will know which treatment is given and what the code referred to. The patients will be instructed to use the treatment twice daily for 6 month duration.~This group will use Cetrizine 1% gel, which will be prepared at the department of Pharmaceutics, Faculty of Pharmacy, Assiut University in the form of Nano-transferosomes (NTF).
Study NCT02563847 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg 13C-sodium acetate
Study NCT02563847 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 50 mg 13C-sodium acetate